Zhaoqi Yan

Aug 28, 2024 | nature.com | Jae Kyu Ryu |Zhaoqi Yan |Mauricio Montano |Karuna Dixit |Rahul Suryawanshi |Yusuke Matsui | +10 more

AbstractLife-threatening thrombotic events and neurological symptoms are prevalent in COVID-19 and are persistent in patients with long COVID experiencing post-acute sequelae of SARS-CoV-2 infection1,2,3,4. Despite the clinical evidence1,5,6,7, the underlying mechanisms of coagulopathy in COVID-19 and its consequences in inflammation and neuropathology remain poorly understood and treatment options are insufficient.